Laboratorios Farmaceuticos Rovi Past Earnings Performance
Past criteria checks 2/6
Laboratorios Farmaceuticos Rovi has been growing earnings at an average annual rate of 40%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 22.5% per year. Laboratorios Farmaceuticos Rovi's return on equity is 31.3%, and it has net margins of 20.5%.
Key information
40.0%
Earnings growth rate
38.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 22.5% |
| Return on equity | 31.3% |
| Net Margin | 20.5% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Laboratorios Farmaceuticos Rovi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 830 | 170 | 123 | 0 |
| 30 Sep 23 | 837 | 197 | 143 | 0 |
| 30 Jun 23 | 818 | 186 | 138 | 0 |
| 31 Mar 23 | 814 | 194 | 134 | 0 |
| 31 Dec 22 | 818 | 200 | 107 | 0 |
| 30 Sep 22 | 761 | 176 | 115 | 0 |
| 30 Jun 22 | 739 | 183 | 110 | 0 |
| 31 Mar 22 | 724 | 182 | 108 | 0 |
| 31 Dec 21 | 649 | 153 | 103 | 0 |
| 30 Sep 21 | 581 | 113 | 95 | 0 |
| 30 Jun 21 | 519 | 82 | 94 | 0 |
| 31 Mar 21 | 450 | 71 | 86 | 0 |
| 31 Dec 20 | 420 | 61 | 85 | 0 |
| 30 Sep 20 | 413 | 55 | 93 | 0 |
| 30 Jun 20 | 395 | 53 | 91 | 0 |
| 31 Mar 20 | 400 | 46 | 93 | 0 |
| 31 Dec 19 | 381 | 39 | 92 | 0 |
| 30 Sep 19 | 355 | 33 | 93 | 0 |
| 30 Jun 19 | 334 | 27 | 93 | 0 |
| 31 Mar 19 | 310 | 18 | 91 | 0 |
| 31 Dec 18 | 303 | 18 | 91 | 0 |
| 30 Sep 18 | 291 | 16 | 90 | 0 |
| 30 Jun 18 | 283 | 9 | 88 | 0 |
| 31 Mar 18 | 284 | 18 | 87 | 0 |
| 31 Dec 17 | 276 | 17 | 85 | 0 |
| 30 Sep 17 | 277 | 22 | 81 | 0 |
| 30 Jun 17 | 275 | 24 | 81 | 0 |
| 31 Mar 17 | 272 | 23 | 80 | 0 |
| 31 Dec 16 | 265 | 26 | 80 | 0 |
| 30 Sep 16 | 260 | 25 | 84 | 0 |
| 30 Jun 16 | 254 | 24 | 84 | 0 |
| 31 Mar 16 | 246 | 23 | 85 | 0 |
| 31 Dec 15 | 246 | 20 | 84 | 0 |
| 30 Sep 15 | 242 | 21 | 53 | -9 |
| 30 Jun 15 | 243 | 23 | 78 | 0 |
| 31 Mar 15 | 241 | 25 | 76 | 0 |
| 31 Dec 14 | 238 | 24 | 75 | 0 |
| 30 Sep 14 | 230 | 24 | 77 | 1 |
| 30 Jun 14 | 224 | 24 | 77 | 0 |
| 31 Mar 14 | 221 | 24 | 78 | 0 |
| 31 Dec 13 | 218 | 23 | 76 | 0 |
| 30 Sep 13 | 209 | 22 | 103 | 8 |
| 30 Jun 13 | 207 | 20 | 76 | 0 |
Quality Earnings: 0ILL has a high level of non-cash earnings.
Growing Profit Margin: 0ILL's current net profit margins (20.5%) are lower than last year (24.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0ILL's earnings have grown significantly by 40% per year over the past 5 years.
Accelerating Growth: 0ILL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0ILL had negative earnings growth (-14.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4%).
Return on Equity
High ROE: 0ILL's Return on Equity (31.3%) is considered high.